Anti-EGFR Antibody, Rabbit Polyclonal (206291-T08)

Anti-EGFR抗体, Rabbit Polyclonal

反应种属:Human
抗原名称:EGFR
应用:IHC
标记:Unconjugated

用户验证的应用

经验证应用

项目详情
IHC-P1:500-1:2000

推荐稀释说明

Optimal concentrations/dilutions should be determined by the end user.

详细信息

免疫原E. coli-derived Human EGFR fragment
宿主/亚型Polyclonal Rabbit IgG
抗体类型Polyclonal
产品类型Antibody
克隆号Polyclonal Rabbit IgG
产品形式Liquid
偶联物Unconjugated
纯化方式Protein A & Antigen Affinity
储存缓冲液PBS, pH7.0 with 0.03% Proclin300
储存条件This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Avoid repeated freeze-thaw cycles.

特异性

Human EGFR

制备方法

Produced in rabbits immunized with E. coli-derived Human EGFR fragment, and purified by antigen affinity chromatography.

运输条件

This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

背景信息

As a member of the epidermal growth factor receptor (EGFR) family, EGFR protein is type I transmembrane glycoprotein that binds a subset of EGF family ligands including EGF, amphiregulin, TGF-α, betacellulin, etc. EGFR protein plays a crucial role in signaling pathway in the regulation of cell proliferation, survival and differentiation. Binding of a ligand induces EGFR protein homo- or heterodimerization, the subsequent tyrosine autophosphorylation and initiates various down stream pathways (MAPK, PI3K/PKB and STAT). In addition, EGFR signaling also has been shown to exert action on carcinogenesis and disease progression, and thus EGFR protein is proposed as a target for cancer therapy currently. Cancer Immunotherapy Immune Checkpoint Immunotherapy Targeted Therapy Full Name epidermal growth factor receptor Research Areas Cancer Drug Targets Receptor Tyrosine Kinases (RTKs) Related Pathways EGFR Signaling Pathway Jak-Stat Signaling Pathway References Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. Cell 103(2): 211-25. Giaccone, G. (2005) HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann. Oncol. 16(4): 538-48. Yarden, Y., et al. (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2(2): 127-37.